| 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2025-026 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 第四届董事会第三十七次会议决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 上海阿拉丁生化科技股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日以现场会议结合通讯方式召开了公司第四届董事会第三十七次会议（以下简称 "本次会议"）。本次会议的通知于 2025 年 4 月 14 日通过书面方式送达全体董事。 会议应出席董事 9 人，实际到会董事 9 人，会议由公司董事长徐久振先生主持， 公司其他相关人员列席会议。本次会议的召集、召开程序符合国家有关法律、法 规和《公司章程》、《董事会议事规则》的规定。本次会议的召开程序、表决结果 均合法有效。 经审议，公司董事会同意公司根据相关法律法规及公司章程的规定编制的 《2024 年度董事会工作报告》。 议案表决结果：同意 9 ...

| 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2025-030 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 关于 2024 年年度利润分配及资本公积转增股本方案 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次利润分配方案不会导致公司触及《上海证券交易所科创板股票上 市规则（2024 年 4 月修订）》（以下简称《科创板股票上市规则》）第 12.9.1 条第一款第（八）项规定的可能被实施其他风险警示的情形（适用于年度分红方 案）。 一、利润分配方案内容 （一）利润分配方案的具体内容 经中审众环会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日， 上海阿拉丁生化科技股份有限公司（以下简称"公司"）母公司报表中期末未分 配利润为人民币 302,772,210.75 元。经董事会决议，公司 2024 年年度拟以实施 权益分派股权登记日登记的总股本扣减公司回购专用证券账户中的股 ...

2、薪酬与考核委员会对符合归属条件的激励对象名单进行审核，发表核查 意见如下： 本次拟归属的激励对象符合《公司法》《证券法》等法律、法规和规范性文 件以及《公司章程》规定的任职资格，符合《管理办法》《上市规则》等法律、 法规和规范性文件规定的激励对象条件，符合本激励计划规定的激励对象范围， 其作为公司本激励计划激励对象的主体资格合法、有效，激励对象获授限制性股 票的归属条件已成就。 1 上海阿拉丁生化科技股份有限公司 董事会薪酬与考核委员会关于公司 2021 年限制性股票激励 计划首次授予部分第三个归属期归属事项的核查意见 上海阿拉丁生化科技股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开第四届董事会薪酬与考核委员会第六次会议，审议通过《关于公司 2021 年限制性股票激励计划首次授予部分第三个归属期符合归属条件的议案》。 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管 理办法》"）、《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"） 等相关法律、法规及规范性文件和《 ...

证券代码：688179 证券简称：阿拉丁 公告编号：2025-034 转债代码：118006 转债简称：阿拉转债 重要内容提示： 上海阿拉丁生化科技股份有限公司（以下简称"阿拉丁"或"公司"）于 2025 年 4 月 23 日召开第四届董事会第三十七次会议、第四届监事会第二十三次 会议审议通过了《关于调整公司 2021 年限制性股票激励计划相关事项的议案》， 同意根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《上 海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）、公司《2021 年限制性股票激励计划（草案）》（以下简称"《激励计划》"、"本激励计划"） 的有关规定，以及公司 2021 年第二次临时股东大会的授权，公司董事会对 2021 年限制性股票激励计划相关事项进行调整，具体情况如下： 一、本次限制性股票激励计划已履行的决策程序和信息披露情况 （一）2021 年 11 月 11 日，公司召开第三届董事会第二十次会议，会议审 议通过了《关于公司<2021 年限制性股票激励计划（草案）>及其摘要的议案》、 《关于公司<2021 年限制性股票激励计划实施考核管理办法>的议案》、《关于 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海阿拉丁生化科技股份有限公司（以下简称"阿拉丁"或"公司"）于 2025 年 4 月 23 日召开的第四届董事会第三十七次会议、第四届监事会第二十三 次会议审议通过了《关于作废部分已授予尚未归属的限制性股票的议案》，现将 相关事项公告如下： 一、本次限制性股票激励计划已履行的决策程序和信息披露情况 1、2021 年 11 月 11 日，公司召开第三届董事会第二十次会议，会议审议通 过了《关于公司<2021 年限制性股票激励计划（草案）>及其摘要的议案》、《关 于公司<2021 年限制性股票激励计划实施考核管理办法>的议案》、《关于提请 股东大会授权董事会办理股权激励相关事宜的议案》。公司独立董事就本激励计 划相关议案发表了独立意见。 同日，公司召开第三届监事会第十六次会议，审议通过了《关于<公司 2021 年限制性股票激励计划（草案）>及其摘要的议案》、《关于<公司 2021 年限制 性股票激励计划实施考核管理办法>的议案》、《关于核查公司<2021 年限制性 股票激励计划 ...

上海阿拉丁生化科技股份有限公司 证券代码：688179 证券简称：阿拉丁 公告编号：2025-035 转债代码：118006 转债简称：阿拉转债 4、激励人数：首次授予人数 128 名，预留授予人数 29 名。 2021 年限制性股票激励计划首次授予部分 第三个归属期符合归属条件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、本次股权激励计划批准及实施情况 （一）本次股权激励计划主要内容 1、股权激励方式：第二类限制性股票。 2、授予数量：本激励计划首次授予数量 97.60 万股，预留授予数量 25.00 万股。 3、授予价格：40 元/股，即满足归属条件后，激励对象可以每股 40 元的价 格购买公司向激励对象增发的公司 A 股普通股股票。 | 第四个归属期 | | 40% | | --- | --- | --- | | 归属安排 | 归属时间 自授予之日起 52 个月后的首个交易日至授予之 日起 64 个月内的最后一个交易日止 | 归属权益数量占授予权 益总量的比例 | （2）公司层面业绩考核 ...

本次拟归属的激励对象符合《公司法》《证券法》等法律、法规和规范性文 件以及《公司章程》规定的任职资格，符合《管理办法》《上市规则》等法律、 法规和规范性文件规定的激励对象条件，符合本激励计划规定的激励对象范围， 其作为公司本激励计划激励对象的主体资格合法、有效，激励对象获授限制性股 票的归属条件已成就。 上海阿拉丁生化科技股份有限公司 监事会关于公司 2021 年限制性股票激励计划首次授予部分 第三个归属期归属名单的核查意见 上海阿拉丁生化科技股份有限公司（以下简称"公司"）监事会根据《中华 人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下 简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管理办法》"）、 《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）等相关法律、 法规及规范性文件和《上海阿拉丁生化科技股份有限公司章程》（以下简称"《公 司章程》"）的有关规定，对公司 2021 年限制性股票激励计划（以下简称"本激 励计划"）首次授予部分第三个归属期符合归属条件的激励对象名单进行审核， 发表核查意见如下： 上海阿拉丁生化科技股份有限公司监事会 20 ...

| 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2025-032 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 关于提请股东大会授权董事会决定以简易程序向特定 对象发行股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本次授权事项概述 根据《上市公司证券发行注册管理办法》、《上海证券交易所科创板上市公司证 券发行上市审核规则》、《上海证券交易所上市公司证券发行与承销业务实施细则》 等相关规定，公司于 2025 年 4 月 23 日召开的第四届董事会第三十七次会议，审议 通过《关于提请股东大会授权董事会办理以简易程序向特定对象发行股票相关事宜 的议案》，同意公司董事会提请股东大会授权董事会决定公司向特定对象发行融资 总额不超过人民币 3 亿元且不超过最近一年末净资产 20%的股票，授权期限自公司 2024 年年度股东大会审议通过之日起至公司 2025 年年度股东大会召开之日止。上 述议案尚需提交公司年度股东 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 130,180,313.51, representing a year-on-year increase of 32.20% compared to CNY 98,473,575.99 in the same period last year[4] - Net profit attributable to shareholders for the same period was CNY 24,182,495.49, up 41.35% from CNY 17,107,659.32 year-on-year[4] - Basic earnings per share rose by 50.00% to CNY 0.09 from CNY 0.06 in the previous year[5] - The company reported a diluted earnings per share of CNY 0.09, consistent with the basic earnings per share, indicating a 50.00% increase year-on-year[5] - Operating profit for Q1 2025 was ¥34,048,976.46, an increase of 74.5% from ¥19,518,862.64 in Q1 2024[19] - The company reported a total comprehensive income of ¥24,281,491.76 for Q1 2025, compared to ¥17,129,834.75 in Q1 2024[20] Cash Flow - The net cash flow from operating activities increased significantly by 130.14%, reaching CNY 33,690,148.03 compared to CNY 14,638,706.12 in the previous year[4] - Cash flow from operating activities for Q1 2025 was ¥33,690,148.03, compared to ¥14,638,706.12 in Q1 2024, indicating a significant improvement[21] - Cash flow from investing activities for Q1 2025 showed a net outflow of ¥41,285,281.53, worsening from a net outflow of ¥22,909,560.12 in Q1 2024[22] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,812,575,716.34, reflecting a 1.92% increase from CNY 1,778,424,528.59 at the end of the previous year[5] - The company's cash and cash equivalents decreased to RMB 421,402,808.68 from RMB 466,796,211.45, reflecting a decline of approximately 9.7%[15] - The total liabilities increased to RMB 659,013,937.99 from RMB 635,252,622.94, representing an increase of about 3.5%[17] - The company's equity attributable to shareholders rose slightly to RMB 1,071,043,938.29 from RMB 1,066,069,573.61, indicating a growth of approximately 0.5%[17] Research and Development - Research and development expenses totaled CNY 17,718,759.55, which is 13.61% of operating revenue, a slight decrease from 14.31% in the previous year[5] - The company experienced a significant increase in research and development expenses, which rose to ¥17,718,759.55 in Q1 2025 from ¥14,095,847.62 in Q1 2024[19] Shareholder Information - The total number of common shareholders at the end of the reporting period was 10,149[9] Investments - The company plans to invest RMB 4,117 million in Shanghai Yamei Biopharmaceutical Technology Co., acquiring a 25% stake[12][13] Inventory and Payables - The company's inventory increased to RMB 536,726,674.45 from RMB 528,264,759.16, showing a growth of about 1.7%[15] - The company's accounts payable rose to RMB 60,214,626.29 from RMB 43,991,332.27, marking an increase of approximately 37%[16] - The company's long-term investments increased to RMB 2,517,744.99 from RMB 2,450,253.26, reflecting a growth of about 2.8%[16] Borrowings - The company reported a decrease in short-term borrowings to RMB 31,487,321.64 from RMB 31,435,162.10, indicating a slight reduction[16]

Dividend and Share Capital - The company plans to distribute a cash dividend of 1.00 RMB per 10 shares, totaling approximately 27.61 million RMB (including tax) based on the remaining total share capital of 276,083,281 shares[6]. - The company intends to increase its share capital by 2 shares for every 10 shares held, resulting in a total increase of 55,216,656 shares, raising the total share capital to 331,299,937 shares[6]. - The company has not distributed any bonus shares in the current year[7]. - The cash dividend for the upcoming year is proposed at 1.00 CNY per 10 shares, with no capital increase or stock distribution planned[174]. - The total cash dividend amount for the last accounting year was 27,608,328.10 CNY, representing 27.95% of the net profit attributable to ordinary shareholders[179]. - The cumulative cash dividend over the last three accounting years amounts to 149,983,278.20 CNY, with an average net profit of 92,454,404.03 CNY, resulting in a cash dividend ratio of 162.22%[181]. Financial Performance - The company's operating revenue for 2024 reached CNY 533.56 million, representing a 32.44% increase compared to CNY 402.88 million in 2023[22]. - Net profit attributable to shareholders for 2024 was CNY 98.76 million, a 15.07% increase from CNY 85.83 million in 2023[22]. - The net cash flow from operating activities increased by 171.59% to CNY 151.52 million, up from CNY 55.79 million in the previous year[22]. - Total assets at the end of 2024 amounted to CNY 1,778.42 million, an 18.12% increase from CNY 1,505.55 million at the end of 2023[23]. - Basic earnings per share for 2024 were CNY 0.36, reflecting a 2.86% increase from CNY 0.35 in 2023[24]. - The company reported that the merger with Yuan Ye Bio contributed CNY 107 million in revenue and CNY 34.60 million in net profit during the second to fourth quarters of 2024[25]. - The company achieved a business revenue of ¥533,555,511.04, representing a year-on-year increase of 32.44%[36]. - The net profit attributable to shareholders reached ¥98,761,868.70, showing a year-on-year growth of 15.07%[36]. Research and Development - Research and development expenses accounted for 11.78% of operating revenue in 2024, down from 12.72% in 2023[24]. - The company invested approximately ¥62.86 million in R&D this year, marking a 22.66% increase from the previous year, although the proportion of R&D investment to operating income decreased by 0.94 percentage points to 11.78%[58]. - In 2024, the company applied for 16 new patents, including 1 domestic invention patent and 6 utility model patents[36]. - The company has developed over 3,200 analytical methods, enhancing its product performance characterization capabilities[70]. - The R&D team includes 4 PhD holders, 87 Master's degree holders, and 113 Bachelor's degree holders, indicating a strong educational background[67]. Market Position and Strategy - The company operates in four major fields: high-end chemistry, life sciences, analytical chromatography, and materials science, with a focus on research reagent production[37]. - The company is committed to the development of domestic research reagents, addressing the gap in the market compared to international competitors[44]. - The company has achieved a significant increase in domestic reagent varieties and quality, establishing a competitive stance against foreign brands due to lower prices and faster service response[47]. - The competitive landscape for high-end research reagents in China is dominated by international giants like Sigma-Aldrich and Thermo Fisher Scientific, while domestic companies are gradually gaining market share[120]. - The company aims to expand its product line in four key areas: high-end chemistry, life sciences, analytical chromatography, and materials science, focusing on R&D capability enhancement and product structure optimization[135]. Risks and Challenges - The company faces risks related to research and development failures, which could slow the introduction of new reagent products and impact sales growth[77]. - The company is at risk of losing core technology due to reliance on key personnel, which could adversely affect its competitive advantage[80]. - The company operates in a highly competitive market dominated by foreign enterprises, resulting in a low market share and increased competition[82]. - The company may experience a decline in profit margins due to increased competition and rising costs of raw materials and labor[87]. - The company faces risks related to inventory depreciation and slow turnover, which could negatively impact cash flow and financial stability[88][89]. Corporate Governance and Management - The company has a governance structure that includes a board of directors with specialized committees for audit, nomination, compensation, and strategy[195]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 4.2794 million RMB[155]. - The total remuneration for core technical personnel at the end of the reporting period amounted to 1.7116 million RMB[155]. - The company has no penalties from securities regulatory agencies in the past three years[156]. - The company is actively revising its stock incentive plan, with multiple proposals submitted for shareholder approval[166]. Environmental Responsibility - The company has established an environmental management system and emergency response mechanism for environmental incidents[193]. - The company reported a chemical oxygen demand (COD) concentration of 23 mg/L, well below the standard limit of 500 mg/L for wastewater discharge[199]. - Total nitrogen concentration was measured at 23 mg/L, which is within the acceptable limit of 70 mg/L[199]. - Total phosphorus concentration was recorded at 3.94 mg/L, significantly lower than the standard limit of 8 mg/L[199]. - The company generated 12.51 tons of waste pharmaceuticals, with a total of 15.789 tons stored at the end of the year[200].